Ardelyx (ARDX)

• Market cap: $1.3B
• 1 day: 0.18%
• 5 days: 0.18%
• 1 month: 4.57%
• 3 months: -6.79%
• 6 months: -0.54%
• Year to date: 7.23%
• 1 year: -38.59%
• 5 years: -20.55%
• 10 years: -79.67%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Employees: 267

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

3% more funds holding

Funds holding: 194 [Q2] → 200 (+6) [Q3]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

3% less call options, than puts

Call options by funds: $17.4M | Put options by funds: $17.9M

2.75% less ownership

Funds ownership: 62.91% [Q2] → 60.17% (-2.75%) [Q3]

11% less capital invested

Capital invested by funds: $1.09B [Q2] → $976M (-$115M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5.50 0% upside
• Avg. target: $7.88 43% upside
• High target: $10 82% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Piper Sandler Christopher Raymond 25% 1-year accuracy 8 / 32 met price target	46% upside $8	Neutral Maintained	27 Jan 2025
HC Wainwright & Co. Ed Arce 51% 1-year accuracy 84 / 164 met price target	0% upside $5.50	Neutral Reiterated	16 Jan 2025
Jefferies Chris Howerton 100% 1-year accuracy 1 / 1 met price target	46% upside $8	Buy Maintained	2 Jan 2025
Citigroup Yigal Nochomovitz 32% 1-year accuracy 14 / 44 met price target	82% upside $10	Buy Maintained	4 Nov 2024